Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced on October 7, 2026, that its Board of Directors has authorized the initiation of a formal strategic process. The company intends to evaluate a broad range of opportunities to maximize the value of its asset portfolio, which includes clinical- and development-stage programs.
The strategic review is at a preliminary stage, and the company has not set a definitive timetable for its completion. Potential outcomes include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, and business combinations.
As part of this process, Cadrenal has engaged Tungsten Advisors as its exclusive strategic financial advisor. The company noted that its pipeline has reached critical clinical and regulatory maturity, anchored by a recent alignment with the U.S. Food and Drug Administration (FDA) on the Phase 3 development pathway for CAD-1005.
Key assets under review include:
- CAD-1005: A first-in-class 12-lipoxygenase (12-LOX) inhibitor in development for heparin-induced thrombocytopenia (HIT), which has received Orphan Drug and Fast Track designations from the FDA.
- Tecarfarin: A Phase 3-ready oral vitamin K antagonist for chronic anticoagulation, including patients with end-stage kidney disease, atrial fibrillation, and implanted left ventricular assist devices.
- Frunexian: An investigational parenteral Factor XIa inhibitor for acute and critical care settings, such as major cardiac surgery.
- CAD-2000: A preclinical, next-generation 12-LOX inhibitor targeting adipo-inflammatory signaling for chronic metabolic and cardiorenal disorders.
The company stated that it has received strong interest from potential strategic partners. Cadrenal does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action.
